Cellectar Biosciences announced positive 12-month follow-up results from its Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia, showing an 83.6% overall response rate and median response duration of 17.8 months. The data meet FDA requirements for accelerated approval and support a confirmatory trial planned for late 2026. The drug showed strong efficacy in patients previously treated with BTK inhibitors, a difficult-to-treat group, and maintained a manageable safety profile. This progress positions iopofosine I 131 as a promising new treatment option for heavily pretreated WM patients with limited alternatives.
C-Lingo, a Hong Kong-based company, introduced a new AI-driven platform on May 23, 2026, to transform Chinese language education in Vietnam. The platform uses a unique "Connected Learning" model combining AI personalization and gamification to enhanc...
The Pentagon has informed Japan that delivery of 400 Tomahawk cruise missiles, ordered in 2024 under a $2.35 billion deal, will face delays of up to two years. This is due to the US military prioritizing replenishment of missile stockpiles heavily us...
Uber Technologies Inc. has made a full takeover offer for Delivery Hero at €33 per share, slightly below Delivery Hero's recent closing price. Prior to the offer, Uber increased its stake in Delivery Hero from about 7% to 19.5%, becoming the largest ...
TAO and NEAR both have market caps near $3 billion but differ significantly in economic fundamentals. NEAR generates 7.6 times more daily app fees and has a deeper DeFi ecosystem with $183 million in total value locked and 37 active protocols. TAO, d...
Infinit (IN) surged nearly 10% on Upbit with a 500% spike in trading volume, reaching about 53.49 billion won in 24-hour turnover. This surge placed Infinit at the top of Upbit's investor sentiment rankings with an 'extreme greed' score of 97, signal...
